|
Leveraging our proprietary nitric oxide technology to address the growing global threat of antibiotic-resistant pathogens. |
About UsVast Therapeutics is a preclinical stage biotechnology company focused on harnessing the unique properties of nitric oxide to treat drug-resistant microbial infections.
|
TechnologyVast Therapeutics’ patented nitric oxide technology is being used to create a new class of antibiotic alternative compounds that deliver broad-spectrum antimicrobial activity without the risk of developing drug resistance common to traditional antibiotics.
|
InvestorsVast Therapeutics is committed to bringing breakthrough therapies to market that address the growing need for novel compounds to treat emerging and antibiotic-resistant respiratory infections.
|
RECENT NEWS
|
Chuck Swoboda named Vast Therapeutics President & CEO
Jan 15, 2021 Vast Therapeutics, Inc announced that Chuck Swoboda has joined the company as President & CEO. Prior to joining the company, he spent more than 25 years at Cree, Inc, where he helped lead the company from $6 million in revenue to over $1.6 billion. During his 16 years as Cree CEO, the company was recognized as one of MIT Technology Review's 50 Smartest Companies and as one of Fast Company's World's 50 Most... |
KNOW Bio Announces Breakthrough Nitric Oxide Discovery to Combat COVID-19
Sep 10, 2020 Research Triangle Park, N.C. (September 10, 2020) – KNOW Bio, LLC has generated the first definitive evidence that nitric oxide (NO) can inhibit viral reproduction of SARS-CoV-2, the human coronavirus that causes COVID-19. Nitric oxide is a molecule produced naturally by the body to regulate blood flow, control inflammation, and defend against invading microorganisms. |
Vast Therapeutics Announces BIOC11 testing results for Nontuberculous Mycobacteria (NTM) in Animal Model
Oct 22, 2019 DURHAM, N.C., Oct. 22, 2019 -- Vast Therapeutics, Inc., a subsidiary of KNOW Bio, LLC, announces that BIOC11 eradicated 99% of the Nontuberculous Mycobacteria (NTM) in an in vivo animal model of infection; this data will be presented at the National Cystic Fibrosis Conference to be held in Nashville, Tennessee from October 31 to November 2, 2019. |
